Search results
14 gru 2023 · This topic review will cover the use of adjuvant HER2-directed therapy plus chemotherapy in patients with HER2-positive, early-stage breast cancer (stage I to III).
19 sie 2024 · This topic will discuss the role of chemotherapy in the adjuvant treatment of early-stage breast cancer, how to estimate the benefit and risk of chemotherapy, the indications for adjuvant chemotherapy, and the dosing and timing of treatment.
7 gru 2022 · The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with breast cancer, both in the adjuvant and neoadjuvant settings.
31 sie 2015 · AC-T is a standard regimen for breast cancers that require treatment with chemotherapy. Women with cancer of a higher grade and younger women often get this combination. It can also be used in people who have had a recurrence depending the medicines you received for early- stage disease.
With pCR as the primary endpoint, the combination of chemotherapy plus dual HER2-targeting agents achieved a pCR rate in breast (ypT0/is) of 45.8%, compared with 29% for trastuzumab and docetaxel, 24% for pertuzumab and docetaxel, and 16.8% for dual HER2 blockade without chemotherapy (P=.0141).
19 cze 2024 · With a primary endpoint of 5-year iDFS, the investigators were able to demonstrate considerable improvements to iDFS for those on a trastuzumab-containing regimen (AC-TH or TCH).
Treatment Guidelines for Patients. Version VIII/September 2006. The mutual goal of the National Comprehensive Cancer Network (NCCN) and the American Cancer Society (ACS) partnership is to provide patients with state-of-the-art cancer treatment information in an easy to understand language.
